TUBB4B
ENSG00000188229
Target class
Structural protein
Chromosome
9
Approved drugs
19
Clinical candidates (approved and in development)
84
- Approved drugs
- 19
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 84
- Chemical probe available
- No
- Other names
- Beta2
- Target name
- TUBB4B
- Gene name
- Tubulin beta 4B class IVb
- Gene symbol
- TUBB4B
- Previous gene symbols
- TUBB2C
- Protein name
- Tubulin beta-4B chain (Tubulin beta-2 chain) (Tubulin beta-2C chain)
- Gene biotype
- Protein coding
- Gene family
- Tubulin beta family
- Target class
- Structural protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 1,825.87
- Tissue specificity (Gini)
- 0.333
- Tissue specificity (tau)
- 0.885
- KEGG gene identifiers
- hsa:10383
- Protein interaction confidence
- 0.830613
- Protein interaction partners
- 75
- R-HSA-1445148
- R-HSA-190840
- R-HSA-190861
- R-HSA-2132295
- R-HSA-2467813
- R-HSA-2500257
- R-HSA-2565942
- R-HSA-3371497
- R-HSA-380259
- R-HSA-380270
- R-HSA-380284
- R-HSA-380320
- R-HSA-389957
- R-HSA-389960
- R-HSA-389977
- R-HSA-437239
- R-HSA-5610787
- R-HSA-5620912
- R-HSA-5620920
- R-HSA-5620924
- R-HSA-5626467
- R-HSA-5663220
- R-HSA-6798695
- R-HSA-6807878
- R-HSA-6811434
And 13 more, listed on the interactive page.
- End position
- 137243707
- Start position
- 137241287
- Chromosome
- 9
- Strand
- Forward
- Cytoplasm, cytoskeleton . Cytoplasm, cytoskeleton, flagellum axoneme .
- Basal body
- Cytokinetic bridge
- End piece
- Flagellar centriole
- Microtubules
- Mitotic spindle
- Primary cilium
- Primary cilium tip
- Principal piece
- Tissue specificity (tau)
- 0.885253
- Expression inequality (Gini)
- 0.333026
Expression in transcripts per million
- Testis
- 1,825.87
- Cells - Cultured fibroblasts
- 702.96
- Esophagus - Mucosa
- 500.56
- Skin - Not Sun Exposed (Suprapubic)
- 374.08
- Cells - EBV-transformed lymphocytes
- 355.32
Expression in transcripts per million
- Testis1,825.87
- Cells - Cultured fibroblasts702.96
- Esophagus - Mucosa500.56
- Skin - Not Sun Exposed (Suprapubic)374.08
- Cells - EBV-transformed lymphocytes355.32
- Esophagus - Muscularis323.04
- Fallopian Tube300.32
- Skin - Sun Exposed (Lower leg)299.02
- Brain - Hypothalamus292.93
- Brain - Frontal Cortex (BA9)292.92
- Esophagus - Gastroesophageal Junction284.88
- Colon - Transverse282.51
- Lung255.43
- Heart - Atrial Appendage248.24
- Heart - Left Ventricle240.29
- Small Intestine - Terminal Ileum239.61
- Pituitary228.88
- Colon - Sigmoid227.63
- Brain - Cortex223.43
- Minor Salivary Gland219.13
- Vagina219.1
- Artery - Coronary216.78
- Brain - Cerebellar Hemisphere211.35
- Prostate208.93
- Artery - Aorta207.86
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0005634
- GO:0005829
- GO:0005856
- GO:0005874
- GO:0005879
- GO:0035578
- GO:0070062
- GO:1903561
- GO:0003725
- GO:0005515
- GO:0042288
Related records
Trials (9,123)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Drugs (89)
- ABT-751 Tubulin beta inhibitor
- AGS-16C3F Tubulin disrupting agent
- Anetumab ravtansine Tubulin inhibitor
- ANG1005 Tubulin inhibitor
- Anvatabart opadotin Tubulin inhibitor
- Aprutumab ixadotin Tubulin inhibitor
- ASG-5ME Tubulin inhibitor
- AVE-9633 Tubulin inhibitor
- Azintuxizumab vedotin Tubulin inhibitor
- Belantamab mafodotin Tubulin inhibitor
- BIIB-015 Tubulin inhibitor
- Bivatuzumab mertansine Tubulin inhibitor
- BMS-275183 Tubulin stabiliser
- Brentuximab vedotin Tubulin inhibitor
- Cabazitaxel Tubulin inhibitor
- Cantuzumab mertansine Tubulin inhibitor
- Cantuzumab ravtansine Tubulin inhibitor
- Colchicine Tubulin inhibitor
- Coltuximab ravtansine Tubulin inhibitor
- Crolibulin Tubulin inhibitor